Long-term outcomes of avelumab maintenance in older patients with advanced urothelial carcinoma in Japan from the JAVEMACS study
The retrospective JAVEMACS chart review study described outcomes of avelumab first-line maintenance for patients with locally advanced/metastatic urothelial carcinoma without progression after platinum-based chemotherapy (PBC) in Japanese real-world practice. This post hoc exploratory analysis compared outcomes by age at avelumab initiation (<75 vs. ≥75 [main] and <80 vs. ≥80 years [supportive]). Stabilized inverse probability of treatment weighting estimated covariate-standardized associations; causal inference was not intended. Overall survival (OS) and progression-free survival (PFS) were assessed using unadjusted and weighted Kaplan-Meier and Cox models. Among 349 patients, 206 (59.0%) and 143 (41.0%) were <75 and ≥75 years, respectively. In the complete-case propensity score analysis set (n = 267), balance improved for most covariates, but some residual imbalance remained and overlap was limited. In the main weighted analyses, there were no statistically significant age-group differences in OS (HR 0.832, 95% CI 0.554–1.248; p = 0.372) and PFS (HR 0.794, 95% CI 0.577–1.093; p = 0.156); supportive results were also not statistically significant. These exploratory observations do not establish equivalence or an age-specific treatment effect, and interpretations should consider the retrospective design, complete-case weighting, limited overlap, and residual confounding. These findings provide descriptive long-term outcomes for older patients receiving avelumab maintenance in Japanese practice.
Authors
- Naotaka Nishiyama (ORCID: https://orcid.org/0000-0003-2017-2312)
- Eiji Kikuchi (ORCID: https://orcid.org/0000-0002-1624-6676)
- Takahito Negishi (ORCID: https://orcid.org/0000-0002-6645-8829)
- Mizuki Kobayashi (ORCID: https://orcid.org/0000-0002-4135-6789)
- Sei Naito (ORCID: https://orcid.org/0000-0002-6104-4344)
- Takuto Hara (ORCID: https://orcid.org/0000-0003-4524-2815)
- Suguru Shirotake (ORCID: https://orcid.org/0000-0002-3581-2039)
- Rikiya Taoka (ORCID: https://orcid.org/0000-0003-3243-499X)
- Toru Sakatani (ORCID: https://orcid.org/0009-0004-4994-1503)
- Junya Furukawa (ORCID: https://orcid.org/0000-0001-8974-9218)
- Masaomi Ikeda (ORCID: https://orcid.org/0000-0003-1017-9799)
- Kiyoaki Nishihara (ORCID: https://orcid.org/0000-0002-1298-3273)
- Junji Yatsuda (ORCID: https://orcid.org/0000-0002-1854-2217)
- Noriyoshi Miura (ORCID: https://orcid.org/0000-0002-2229-0948)
- Takashige Abe (ORCID: https://orcid.org/0000-0002-5468-7632)
- Daiki Ikarashi (ORCID: https://orcid.org/0000-0001-8088-2848)
- Norihiko Kawamura
- Naoya Masumori (ORCID: https://orcid.org/0000-0001-6324-0739)
- Atsuko Fujihara (ORCID: https://orcid.org/0000-0001-5213-3831)
- Michihiro Shono
- Kan Yonemori (ORCID: https://orcid.org/0000-0002-7624-7611)
- Masayoshi Nagata
- Tohru Nakagawa
- Takashi Kobayashi
- Kiyohide Fujimoto
- Shingo Hatakeyama
- Nozomi Hayakawa
- Yuki Endo
- Hiroshi Kitamura
- Kazutoshi Fujita
Institutions
- Kurume University (JP)
- Yamagata University (JP)
- Sapporo Medical University (JP)
- Hirosaki University (JP)
- St. Marianna University School of Medicine (JP)
- Iwate Medical University (JP)
- Kagawa University (JP)
- Akita University (JP)
- Hokkaido University (JP)
- Kyoto University (JP)
- Juntendo University (JP)
- Kyoto Prefectural University of Medicine (JP)
- National Hospital Organization Kyushu Cancer Center (JP)
- Merck Biopharma Co., Ltd. (Japan) (JP)
- Saitama International Medical Center (JP)
- Osaka International Cancer Institute (JP)
- Nippon Medical School Hospital (JP)
- University of Toyama (JP)
- Ehime University (JP)
- National Cancer Center Hospital (JP)
- Kitasato University (JP)
- Nara Medical University (JP)
- Kobe University (JP)
- Saitama Medical University (JP)
- Teikyo University (JP)
- Kindai University (JP)
- Tokushima University (JP)
- Kumamoto University (JP)
Publication Details
- Journal
- Scientific Reports
- Published
- 2026-11-20
- DOI
- https://doi.org/10.1038/s41598-026-79463-5
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Merck KGaA